IN2012DN06720A - - Google Patents

Info

Publication number
IN2012DN06720A
IN2012DN06720A IN6720DEN2012A IN2012DN06720A IN 2012DN06720 A IN2012DN06720 A IN 2012DN06720A IN 6720DEN2012 A IN6720DEN2012 A IN 6720DEN2012A IN 2012DN06720 A IN2012DN06720 A IN 2012DN06720A
Authority
IN
India
Prior art keywords
disease
treatment
present disclosure
disclosure relates
pharmaceutical formulations
Prior art date
Application number
Inventor
Dingjiang Liu
Holly Zhuohong Huang
David Andrew Martin
Christopher Boyd Russell
David H Salinger
Scott Walter Baumgartner
Christopher J Endres
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN06720(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kirin Amgen Inc filed Critical Kirin Amgen Inc
Publication of IN2012DN06720A publication Critical patent/IN2012DN06720A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)

Abstract

The present disclosure relates to AM 14 pharmaceutical formulations and therapeutic dosing regimens for the treatment of disease.
IN6720DEN2012 2010-01-15 2011-01-12 IN2012DN06720A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29538710P 2010-01-15 2010-01-15
US42205910P 2010-12-10 2010-12-10
PCT/US2011/020985 WO2011088120A1 (en) 2010-01-15 2011-01-12 Antibody formulation and therapeutic regimens

Publications (1)

Publication Number Publication Date
IN2012DN06720A true IN2012DN06720A (en) 2015-10-23

Family

ID=43858045

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6720DEN2012 IN2012DN06720A (en) 2010-01-15 2011-01-12

Country Status (38)

Country Link
US (5) US8883151B2 (en)
EP (3) EP2523688B1 (en)
JP (2) JP5743234B2 (en)
KR (1) KR101766936B1 (en)
CN (1) CN102821787B (en)
AR (1) AR079903A1 (en)
AU (3) AU2011205402B2 (en)
BR (1) BR112012017150B1 (en)
CA (1) CA2787128C (en)
CL (1) CL2012001966A1 (en)
CO (1) CO6640206A2 (en)
CR (1) CR20120419A (en)
CY (2) CY1119852T1 (en)
DK (2) DK3295957T3 (en)
EA (2) EA201891433A3 (en)
ES (2) ES2753216T3 (en)
HR (1) HRP20171939T1 (en)
HU (2) HUE035618T2 (en)
IL (1) IL220602B (en)
IN (1) IN2012DN06720A (en)
LT (2) LT3295957T (en)
MA (1) MA33989B1 (en)
MX (1) MX349856B (en)
MY (1) MY182680A (en)
NO (1) NO2523688T3 (en)
NZ (1) NZ601125A (en)
PE (1) PE20121691A1 (en)
PH (1) PH12012501364A1 (en)
PL (2) PL3295957T3 (en)
PT (2) PT3295957T (en)
RS (2) RS56781B1 (en)
SG (2) SG10201604093XA (en)
SI (2) SI3295957T1 (en)
TN (1) TN2012000335A1 (en)
TW (1) TWI554282B (en)
UA (1) UA112288C2 (en)
WO (1) WO2011088120A1 (en)
ZA (1) ZA201205167B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
JO3244B1 (en) 2009-10-26 2018-03-08 Amgen Inc Proteins bind to human IL-23 antigens
PL3295957T3 (en) 2010-01-15 2020-03-31 Kirin-Amgen, Inc. Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis
EP2531218B1 (en) 2010-02-04 2018-12-12 CSL Behring AG Immunoglobulin preparation
MX2012013490A (en) 2010-05-20 2013-01-29 Ablynx Nv BIOLOGICAL MATERIALS RELATED TO HER3.
JP6159660B2 (en) 2010-09-22 2017-07-05 アムジエン・インコーポレーテツド Immunoglobulins as carriers and uses thereof
US20140023655A1 (en) * 2011-04-07 2014-01-23 Glaxosmithkline Llc Formulations with reduced viscosity
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
JOP20200043A1 (en) * 2011-05-10 2017-06-16 Amgen Inc Ways to treat or prevent cholesterol disorders
US20140234330A1 (en) * 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
MX366936B (en) 2011-11-23 2019-07-31 Amgen Inc Administration of alpha4beta7 hetero-dimer-specific antibody.
BR112014021308B1 (en) * 2012-03-07 2022-08-30 Eli Lilly And Company PHARMACEUTICAL FORMULATIONS OF ANTIBODIES
WO2013170977A1 (en) 2012-05-14 2013-11-21 Novo Nordisk A/S Stabilised protein solutions
JP2016517408A (en) 2013-03-15 2016-06-16 アムジェン インコーポレイテッド Method for treating psoriasis using anti-IL-23 antibody
WO2014143540A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
AU2015241373B2 (en) * 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
KR102427097B1 (en) * 2014-08-26 2022-08-01 암젠 케이-에이, 인크. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
WO2016039319A1 (en) * 2014-09-10 2016-03-17 日油株式会社 Protein adsorption inhibitor and method for inhibiting protein adsorption
CA2968915A1 (en) 2014-12-03 2016-06-09 Csl Behring Ag Pharmaceutical product with increased stability comprising immunoglobulins
AR103173A1 (en) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
HK1258292A1 (en) 2015-09-17 2019-11-08 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
JP2018538249A (en) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil targeted therapeutics in eosinophilic diseases
JP2019508370A (en) 2015-12-22 2019-03-28 アムジェン インコーポレイテッド CCL20 as a Predictor of Clinical Response to IL23 Antagonists
CN114265251B (en) 2016-04-19 2024-12-06 Sage电致变色显示有限公司 Electrochromic device including a transparent conductive oxide layer and a bus bar and a method of forming the same
GB201612043D0 (en) * 2016-07-11 2016-08-24 Crescendo Biologics Ltd Composition for treatment of disorders
CA2974531A1 (en) * 2017-07-26 2019-01-26 Michael Giroux Safety anchor and roof vent
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
EP3820897A2 (en) 2018-07-13 2021-05-19 Astrazeneca Collaboration Ventures, LLC Treating ulcerative colitis with brazikumab
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
WO2021050563A1 (en) * 2019-09-09 2021-03-18 The Rockefeller University Antibody treatment for lesional tissue of hidradenitis suppurativa
CN114401993A (en) 2019-09-11 2022-04-26 博世健康爱尔兰有限公司 Methods of treating non-alcoholic fatty liver disease (NAFLD) using IL-17RA antibodies
UY39089A (en) * 2020-02-18 2021-08-31 Amgen Inc FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF USE OF THE SAME
CN111840217B (en) * 2020-06-19 2021-04-02 北京东方百泰生物科技股份有限公司 Injection preparation of anti-IL-17 RA monoclonal antibody
CN117615788A (en) * 2021-05-12 2024-02-27 安奈普泰斯生物有限公司 Antibody compositions
EP4537345A1 (en) * 2022-06-06 2025-04-16 Fusion Pharmaceuticals Inc. Methods of dosing therapeutic agents

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1000835A (en) 1911-06-19 1911-08-15 Stewart A Minnick Calipers.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
IL83878A (en) 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
GB8807803D0 (en) 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
FI895955A7 (en) 1988-04-15 1989-12-13 Protein Design Labs Inc IL-2 receptor-specific "chimeric" antibodies
IL94039A (en) 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
ATE289350T1 (en) 1989-04-21 2005-03-15 Amgen Inc TNF RECEPTOR, TNF BINDING PROTEINS AND DNA CODING THEREOF
DE3922089A1 (en) 1989-05-09 1990-12-13 Basf Ag NEW PROTEINS AND THEIR PRODUCTION
EP0398327B2 (en) 1989-05-18 2013-02-20 Yeda Research And Development Co., Ltd. Tumor necrosis factor binding protein II, its purification and antibodies thereto
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5703088A (en) 1989-08-21 1997-12-30 Beth Israel Deaconess Medical Center, Inc. Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses
CA2485553A1 (en) 1989-09-05 1991-03-21 Immunex Corporation Tumor necrosis factor - .alpha. and - .beta. receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (en) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
JPH03127800A (en) 1989-10-13 1991-05-30 Teijin Ltd Tumor necrosis factor activity inhibitor
DE69022559T2 (en) 1989-12-13 1996-05-02 Yeda Res & Dev Expression of the recombinant tumor necrosis factor binding protein I (TBP-I).
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5136021A (en) 1990-02-27 1992-08-04 Health Research, Inc. TNF-inhibitory protein and a method of production
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
GB2243569A (en) 1990-05-02 1991-11-06 Andrew Langdon Brush with timer
DK0835939T3 (en) 1990-06-28 2006-03-13 Sanofi Aventis Deutschland Fusion proteins with proportions of immunoglobulin, their preparation and use
WO1992001002A1 (en) 1990-07-11 1992-01-23 Teijin Limited Tumor necrosis factor activity inhibitor and production thereof
DE69230789T3 (en) 1991-01-18 2007-10-31 Amgen Inc., Thousand Oaks METHODS OF TREATING ILLNESSES RELEASED BY THE TUMOR NEKROSE FACTOR
DK0575545T3 (en) 1991-03-15 2003-09-15 Amgen Inc Pegylation of polypeptides
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5770401A (en) 1991-10-15 1998-06-23 Mullarkey; Michael F. Methods and compositions for treating allergic reactions
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
ATE207080T1 (en) 1991-11-25 2001-11-15 Enzon Inc MULTIVALENT ANTIGEN-BINDING PROTEINS
NZ251820A (en) 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
WO1993021946A1 (en) 1992-04-30 1993-11-11 Synergen, Inc. Methods for treating interleukin-1 and tumor necrosis factor mediated diseases
JPH05312248A (en) 1992-05-08 1993-11-22 Nissan Motor Co Ltd Shift level device
WO1994006476A1 (en) 1992-09-15 1994-03-31 Immunex Corporation Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
WO1996029408A1 (en) 1995-03-23 1996-09-26 Immunex Corporation Il-17 receptor
EP1591529A3 (en) 1995-07-19 2005-11-09 Genetics Institute, LLC Human CLTA-8 and uses of CTLA-8-related proteins
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
AU7408998A (en) 1996-11-27 1998-06-22 Immunex Corporation Method of regulating nitric oxide production
KR100643058B1 (en) 1996-12-03 2006-11-13 아브게닉스, 인크. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2333385T3 (en) 1997-09-17 2010-02-19 Human Genome Sciences, Inc. PROTEIN OF THE INTERLEUQUINE TYPE-17.
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
IL138930A0 (en) 1998-05-15 2001-11-25 Genentech Inc Il-17 homologies polypeptides and therapeutic uses thereof
JP2000247903A (en) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd Long-term stabilized pharmaceutical preparation
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
PL211886B1 (en) 1999-10-04 2012-07-31 Novartis Vaccines & Diagnostic Stabilized liquid polypeptide-containing pharmaceutical compositions
AR028256A1 (en) 2000-03-16 2003-04-30 Amgen Inc SIMILAR MOLECULES TO IL-17 RECEPTORS AND USES OF THE SAME
AR030554A1 (en) 2000-03-16 2003-08-27 Amgen Inc SIMILAR MOLECULES TO IL-17 RECEPTORS AND USES OF THE SAME
US20030180255A1 (en) 2000-08-24 2003-09-25 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
JP2004517918A (en) 2000-10-18 2004-06-17 イミュネックス・コーポレーション Treatment of rheumatoid arthritis using an IL-17 antagonist
SI1478394T1 (en) 2002-02-27 2008-12-31 Immunex Corp Stabilized TNFR-Fc composition comprising arginine
AU2003280017A1 (en) 2002-06-27 2004-01-19 Smithkline Beecham Corporation Methods of treating or preventing ibd with il-18
ATE328906T1 (en) 2002-06-28 2006-06-15 Domantis Ltd DUAL-SPECIFIC LIGANDS WITH INCREASED HALF-LIFE
DE10333317A1 (en) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulation for protein medicines without the addition of human serum albumin (HSA)
JP2007501251A (en) 2003-08-05 2007-01-25 スリーエム イノベイティブ プロパティズ カンパニー Infection prevention using immune response modifier compounds
GB0321703D0 (en) * 2003-09-16 2003-10-15 Imerys Minerals Ltd Surface modified fillers for polymer resin compositions
EP1712240B1 (en) 2003-12-25 2015-09-09 Kyowa Hakko Kirin Co., Ltd. Stable water-based medicinal preparation containing antibody
IL159670A0 (en) 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
MXPA06014053A (en) 2004-06-04 2007-07-11 Designer Molecules Inc Free-radical curable polyesters and methods for use thereof.
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
AU2006214384A1 (en) 2005-02-14 2006-08-24 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of IL-17F in diagnosis and therapy of airway inflammation
US20080311078A1 (en) 2005-06-14 2008-12-18 Gokarn Yatin R Self-Buffering Protein Formulations
CA2615122A1 (en) 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
WO2007037795A2 (en) 2005-08-05 2007-04-05 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
JP2009507023A (en) 2005-09-01 2009-02-19 シェーリング コーポレイション Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory diseases
US20070129302A1 (en) 2005-10-18 2007-06-07 Zeren Gao Il-17c antagonists and methods of using the same
US20070135343A1 (en) 2005-11-01 2007-06-14 Wyeth Sodium chloride solution for drug reconstitution or dilution
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
AU2007212147A1 (en) * 2006-02-03 2007-08-16 Medimmune, Llc Protein formulations
CN101541833B (en) * 2006-10-02 2014-01-29 麒麟-安姆根有限公司 IL-17 receptor A antigen-binding protein
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2064237A2 (en) 2006-10-18 2009-06-03 ZymoGenetics, Inc. Il-17c antagonists and methods of using the same
FR2910324B1 (en) 2006-12-21 2009-03-06 Biomerieux Sa NEW MEDICINE FOR THE TREATMENT OF GASTRIC CANCER
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
JP2010522564A (en) 2007-03-26 2010-07-08 ザイモジェネティクス， インコーポレイテッド Soluble IL-17RA / RC fusion protein and related methods
EP2170958A1 (en) 2007-06-13 2010-04-07 Amgen Inc. Il-17 heteromeric receptor complex
WO2009006301A2 (en) 2007-06-29 2009-01-08 Battelle Memorial Institute Protein stabilization
WO2009026122A1 (en) 2007-08-17 2009-02-26 Amgen Inc. Formulations of antibodies and fc-fusion molecules using polycations
KR101240904B1 (en) 2008-02-21 2013-03-11 키린-암젠 인코포레이티드 Il-17ra-il-17rb antagonists and uses thereof
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
PL3295957T3 (en) * 2010-01-15 2020-03-31 Kirin-Amgen, Inc. Anti il-17ra antibody formulation and therapeutic regimens for treating psoriasis
ES2660770T3 (en) 2010-10-08 2018-03-26 Novartis Ag Methods for the treatment of psoriasis using IL-17 antagonists
US20120201821A1 (en) 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
EP2694708A4 (en) * 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS WITH REDUCED VISCOSITY
US20140023655A1 (en) * 2011-04-07 2014-01-23 Glaxosmithkline Llc Formulations with reduced viscosity
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
AU2015241373B2 (en) 2014-03-31 2020-11-05 Amgen K-A, Inc. Methods of treating nail and scalp psoriasis
KR102427097B1 (en) 2014-08-26 2022-08-01 암젠 케이-에이, 인크. Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy

Also Published As

Publication number Publication date
US20180346583A1 (en) 2018-12-06
ES2753216T3 (en) 2020-04-07
IL220602B (en) 2019-03-31
CY1122466T1 (en) 2020-10-14
RS59743B1 (en) 2020-02-28
EP3632466A1 (en) 2020-04-08
SG10201604093XA (en) 2016-07-28
EA201290653A1 (en) 2013-02-28
US10808033B2 (en) 2020-10-20
TWI554282B (en) 2016-10-21
KR101766936B1 (en) 2017-08-09
PE20121691A1 (en) 2012-12-14
AU2011205402B2 (en) 2015-02-05
EA031209B1 (en) 2018-12-28
CO6640206A2 (en) 2013-03-22
ES2652637T3 (en) 2018-02-05
DK3295957T3 (en) 2019-10-14
EP2523688A1 (en) 2012-11-21
US20230192873A1 (en) 2023-06-22
US8883151B2 (en) 2014-11-11
ZA201205167B (en) 2013-03-27
PH12012501364A1 (en) 2012-10-22
JP2015052017A (en) 2015-03-19
LT2523688T (en) 2018-03-12
EA031209B9 (en) 2021-11-19
DK2523688T3 (en) 2017-12-04
CA2787128A1 (en) 2011-07-21
MX2012008213A (en) 2012-11-06
US10072085B2 (en) 2018-09-11
US20130022621A1 (en) 2013-01-24
JP2013517277A (en) 2013-05-16
HRP20171939T1 (en) 2018-03-23
CY1119852T1 (en) 2018-06-27
EP3295957A1 (en) 2018-03-21
UA112288C2 (en) 2016-08-25
EP3295957B1 (en) 2019-08-07
HUE035618T2 (en) 2018-05-28
EP2523688B1 (en) 2017-10-11
AU2015202023B2 (en) 2017-05-18
RS56781B1 (en) 2018-04-30
SI3295957T1 (en) 2020-02-28
LT3295957T (en) 2020-01-27
SG182468A1 (en) 2012-08-30
CR20120419A (en) 2012-11-29
PL2523688T3 (en) 2018-04-30
PL3295957T3 (en) 2020-03-31
WO2011088120A1 (en) 2011-07-21
EA201891433A3 (en) 2019-02-28
EA201891433A2 (en) 2018-11-30
CL2012001966A1 (en) 2013-01-18
TW201129382A (en) 2011-09-01
HUE046670T2 (en) 2020-03-30
NO2523688T3 (en) 2018-03-10
MA33989B1 (en) 2013-02-01
US11505612B2 (en) 2022-11-22
CN102821787A (en) 2012-12-12
WO2011088120A8 (en) 2012-09-13
AU2017216579A1 (en) 2017-09-07
BR112012017150A2 (en) 2017-10-10
US20150017184A1 (en) 2015-01-15
AU2011205402A1 (en) 2012-07-12
PT2523688T (en) 2018-01-05
US20200399384A1 (en) 2020-12-24
NZ601125A (en) 2014-08-29
AR079903A1 (en) 2012-02-29
MY182680A (en) 2021-01-29
CA2787128C (en) 2019-06-11
MX349856B (en) 2017-08-16
BR112012017150B1 (en) 2022-03-03
PT3295957T (en) 2019-11-12
CN102821787B (en) 2015-07-29
SI2523688T1 (en) 2018-03-30
AU2015202023A1 (en) 2015-05-14
WO2011088120A9 (en) 2012-08-09
TN2012000335A1 (en) 2013-12-12
JP5743234B2 (en) 2015-07-01
KR20120118036A (en) 2012-10-25

Similar Documents

Publication Publication Date Title
IN2012DN06720A (en)
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
MX344238B (en) Tetrazole compounds and methods of making and using same.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
IN2014DN09434A (en)
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
IN2015DN00376A (en)
MX392150B (en) CANABINOID RECEPTOR MODULATORS.
MX347734B (en) S100a4 antibodies and therapeutic uses thereof.
EA201201658A1 (en) DERIVATIVES OF PIPERIDINE AND THEIR APPLICATION FOR THE TREATMENT OF METABOLIC DISORDERS
ZA201108305B (en) Novel p2x7r antagonists and their use
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
PH12014500250A1 (en) Substituted 3-(biphenyl-3-yl)-4 -hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
IN2015DN03921A (en)
PH12012501389A1 (en) Hedgehog inhibitors
UY33219A (en) CYCLIC CETOENOLS FOR THERAPIES
MX2013002118A (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
GB201317815D0 (en) Oral supplementation for the reversal of human hair canities
EA201500446A1 (en) PHARMACEUTICAL COMPOSITION TO REDUCE N-OXIDE TRIMETYLAMINE LEVEL
UA112981C2 (en) OPTION OF HUMAN GDNF
MX2013002295A (en) Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators.
PH12013501638A1 (en) (5s,8s)-3-(4`-chlor-3`-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment
TR201200212A2 (en) Enhanced formulations containing risedronate.
TR201200215A2 (en) Improved pharmaceutical formulations.